文献速递免疫规划卫生政策与健康促进

中国成人甲型肝炎疫苗接种的成本效果:决策树马尔可夫模型研究

Cost-effectiveness of hepatitis A vaccination for adults in China: A decision tree Markov model study.
PubMed 文献 · Vaccine · 2026-03-23

本研究采用决策树马尔可夫模型,从社会视角评估中国≥20岁成人甲肝疫苗接种策略的成本效果。在10万人队列中,四种策略较不接种可预防4024–4180例甲肝,均具成本节约性;血清学筛查后接种单剂减毒活疫苗为最具成本节约的策略。

要点

  • 中国成人甲肝疫苗接种较不接种可节约成本并预防甲肝病例。
  • 接种前血清学筛查可带来额外成本节约。
  • 筛查后接种单剂减毒活疫苗是最具成本节约的策略。

核心结论

  • 中国成人甲肝疫苗接种较不接种可节约成本,接种前血清学筛查可进一步节约成本。
  • 筛查后接种单剂减毒活疫苗是20–78岁人群最具成本节约的策略。

研究设计与样本

  • 决策树马尔可夫模型,从社会视角评估多种成人甲肝疫苗接种策略。
  • 模型参数来自既往发表数据,队列为10万名20–78岁个体。

主要发现

  • 四种疫苗接种策略在10万人队列中预防4024–4180例甲肝。
  • 在支付意愿阈值为中国一次人均GDP时,所有策略较不接种均具成本节约性,每获得一个QALY的增量节约为1584–2733美元。
  • 标准增量分析中,筛查后接种单剂减毒活疫苗是最具成本效果的选择。
  • 两种不筛查策略被筛查策略支配,敏感性分析结果稳健。

关键数值与推荐

  • 支付意愿阈值为中国一次人均GDP。
  • 增量成本效果比相对于不接种状态计算。

临床怎么用

  • 可为政策制定者调整和优化成人甲肝免疫策略提供循证依据。
  • 在成人甲肝疫苗接种规划中,可优先考虑接种前血清学筛查后接种单剂减毒活疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the hepatitis A vaccine has been introduced into in China's National Immunization Program for many years, an immunity gap persists among young adults, posing a continued risk of hepatitis A outbreaks. This study aimed to evaluate the cost-effectiveness of hepatitis A vaccination in adults (≥20 years). METHODS: We developed a decision tree Markov model to evaluate various hepatitis A vaccination strategies from a societal perspective, incorporating parameters derived from previously published data. The strategies included serological screening followed by vaccination of susceptible individuals, as well as vaccination without prior screening. Both live attenuated and inactivated vaccines were considered. The incremental cost-effectiveness ratio (ICER) of each strategy was calculated relative to the status quo (no vaccination). The robustness of the findings was assessed through one-way deterministic sensitivity analysis and probabilistic sensitivity analysis. RESULTS: In a cohort of 100,000 individuals aged 20-78 years, the four vaccination strategies prevented 4024-4180 hepatitis A cases. Compared to no vaccination, all strategies were cost-saving at a willingness-to-pay threshold of one time China's per capita GDP, with incremental savings of $1584-$2733 per QALY gained. However, when applying standard incremental analysis to compare active strategies, screening followed by single-dose live attenuated hepatitis A vaccine (HepA-L) was the most cost-effective option compared to the previous non-dominated option. The two non-screening strategies were dominated by screening-based strategies. Results remained robust across sensitivity analyses. CONCLUSION: Compared to the status quo (no vaccination), hepatitis A vaccination in Chinese adults is cost-saving, while pre-vaccination serological screening yields additional cost savings. Screening followed by administration of a single-dose of live attenuated hepatitis A vaccine (HepA-L) for the population aged 20-78 years was the most cost-saving strategy. Our findings offer evidence-based support for the future adjustment and optimization of immunization strategies for policymakers.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Huang A, Li J, Tang L, et al. Cost-effectiveness of hepatitis A vaccination for adults in China: A decision tree Markov model study. Vaccine. 2026. PMID: 41875689. doi:10.1016/j.vaccine.2026.128509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。